CALQUENCE (acalabrutinib) is indicated: in combination with obinutuzumab or as monotherapy for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); as monotherapy for the treatment of patients with CLL/SLL who have received at least one prior therapy; for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Sign Out
